Lazard Asset Management
PRQR icon

Lazard Asset Management’s ProQR Therapeutics PRQR Stock Holding History

Lazard Asset Management’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-103
Closed – – 2520
2024
Q4 		$0 Hold
103
– – ﹤0.01% 2479
2024
Q3 		$0 Sell
103
-173
-63% -$325 ﹤0.01% 2414
2024
Q2 		$0 Sell
276
-3,871
-93% -$7.52K ﹤0.01% 2387
2024
Q1 		$9K Sell
4,147
-1,713
-29% -$3.66K ﹤0.01% 1877
2023
Q4 		$11K Sell
5,860
-354
-6% -$544 ﹤0.01% 2092
2023
Q3 		$7K Buy
6,214
+302
+5% +$475 ﹤0.01% 2164
2023
Q2 		$9K Buy
5,912
+155
+3% +$303 ﹤0.01% 2191
2023
Q1 		$12K Buy
+5,757
New +$17.6K ﹤0.01% 2115

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Lazard Asset Management's PRQR Position: Q1 2025 in Review

Lazard Asset Management sold out of ProQR Therapeutics (PRQR) in Q1 2025, closing a stake of 103 shares.

Lazard Asset Management first reported a position in PRQR in Q1 2023 and held it in 8 quarters. The position peaked at $12K in Q1 2023. 65 funds tracked by Wall St. Rank hold PRQR as of Q1 2025.

  • Lazard Asset Management reported no remaining ProQR Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 103 ProQR Therapeutics shares in Q1 2025.
  • Lazard Asset Management first reported a position in ProQR Therapeutics in Q1 2023 and held it in 8 quarters.
  • Lazard Asset Management's ProQR Therapeutics position peaked at $12K in Q1 2023.
  • 65 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.